Evaluation of the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura

• Main Authors: Wu-Qiong Duan, Chang-Huai Zhou, Ming-Hai Luo
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2017-07-01
• Series: Journal of Hainan Medical University
• Subjects: Henoch-Schonlein purpura; Montelukast; Loratadine; Tanshinone; Immune response
• Online Access: http://www.hnykdxxb.com/PDF/201713/15.pdf

Objective: To evaluate the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura. Methods: A total of 80 patients with Henoch-Schonlein purpura who were treated in Ankang Central Hospital between May 2014 and January 2017 were collected and divided into montelukast group, loratadine group, tanshinone group and combined treatment group according to the random number table, 20 cases in each group. Serum levels of inflammatory factors, Th17/ Treg cellular immunity indexes before and after treatment were compared among four groups of patients. Results: Before treatment, differences in serum levels of inflammatory factors and Th17/Treg cellular immunity indexes were not statistically significant among four groups of patients. After treatment, serum HMGB1, IL-8, IL-14, IL-23 and IL-33 levels in combined treatment group were lower than those in montelukast group, loratadine group and tanshinone group; serum IL-17 level was lower than that in montelukast group, loratadine group and tanshinone group while IL-10 and TGF-β levels were higher than those in montelukast group, loratadine group and tanshinone group. Conclusions: Montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura helps to reduce systemic inflammatory response and balance Th17/Treg cell immunity.